Literature DB >> 1674284

Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites.

A D Blake1, R G Smith.   

Abstract

The hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP-6) and GH-releasing factor (GHRH) produced a rapid release of GH upon perifusion of dispersed rat pituitary cells. In contrast to the native hormone GHRH, GHRP-6 elicited a response of short duration. When perifusion of each secretagogue was continued until the cells no longer released GH, a challenge by the alternative secretagogue immediately resulted in a secondary release of GH. These results are consistent with each secretagogue causing desensitization of discrete receptor-linked second messenger pathways. Cells which were perifused for 1 min with GHRP-6 required continued perifusion with culture medium alone for 60 min before they completely regained responsiveness to a subsequent challenge with GHRP-6. Somatostatin (SRIF) was able to inhibit the action of either secretagogue completely. However, when both GHRH and GHRP-6 were perifused together, SRIF attenuated but did not block GH secretion. These perifusion data add support to conclusions derived from static cell culture studies, that GHRH and GHRP-6 act through different receptor sites and that through discrete signalling pathways their individual effects on GH release are amplified.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1674284     DOI: 10.1677/joe.0.1290011

Source DB:  PubMed          Journal:  J Endocrinol        ISSN: 0022-0795            Impact factor:   4.286


  17 in total

1.  Hexarelin is a stronger GH-releasing peptide than GHRH in normal cycling women but not in anorexia nervosa.

Authors:  M Giusti; L Foppiani; P Ponzani; C M Cuttica; M R Falivene; S Valenti
Journal:  J Endocrinol Invest       Date:  1997-05       Impact factor: 4.256

Review 2.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Differential regulation of GHRH-receptor and GHS-receptor expression by long-term in vitro treatment of ovine pituitary cells with GHRP-2 and GHRH.

Authors:  Sang-Gun Roh; Maria Doconto; Dan Dan Feng; Chen Chen
Journal:  Endocrine       Date:  2006-08       Impact factor: 3.633

4.  GH responsiveness to repeated GHRH or hexarelin administration in normal adults.

Authors:  A Sartorio; A Conti; S Ferrero; A Spada; G Faglia
Journal:  J Endocrinol Invest       Date:  1995-10       Impact factor: 4.256

5.  Hexarelin-induced growth hormone response in short stature. Comparison with growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen.

Authors:  G Guzzaloni; G Grugni; F Morabito
Journal:  J Endocrinol Invest       Date:  1999-05       Impact factor: 4.256

6.  Growth hormone secretagogues: characterization, efficacy, and minimal bioactive conformation.

Authors:  R S McDowell; K A Elias; M S Stanley; D J Burdick; J P Burnier; K S Chan; W J Fairbrother; R G Hammonds; G S Ingle; N E Jacobsen; D L Mortensen; T E Rawson; W B Won; R G Clark; T C Somers
Journal:  Proc Natl Acad Sci U S A       Date:  1995-11-21       Impact factor: 11.205

7.  Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro.

Authors:  R D Orkin; D I New; D Norman; S L Chew; A J L Clark; A B Grossman; M Korbonits
Journal:  J Endocrinol Invest       Date:  2003-08       Impact factor: 4.256

8.  Arginine enhances the growth hormone-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration.

Authors:  E Ghigo; E Arvat; G Rizzi; J Bellone; M Nicolosi; G M Boffano; M Mucci; M F Boghen; F Camanni
Journal:  J Endocrinol Invest       Date:  1994-03       Impact factor: 4.256

9.  Exogenous growth hormone administration does not inhibit the growth hormone response to hexarelin in normal men.

Authors:  M Cappa; S Setzu; S Bernardini; D Carta; G Federici; A Grossi; S Loche
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

10.  Ghrelin improves growth hormone responses to growth hormone-releasing hormone in a streptozotocin-diabetic model of delayed onset.

Authors:  Y Diz-Chaves; C Spuch; D Pérez; F Mallo
Journal:  J Endocrinol Invest       Date:  2007-04       Impact factor: 4.256

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.